Chimeric Therapeutics Limited (CHMMF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Chimeric Therapeutics Limited (CHMMF) trades at $0.10 with AI Score 56/100 (Grade B). Chimeric Therapeutics Limited is an Australian clinical-stage cell therapy company focused on developing and commercializing innovative oncology treatments. Market cap: $4.10M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for CHMMF: CHMMF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CHMMF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CHMMF: the 4 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →Chimeric Therapeutics Limited (CHMMF) Healthcare & Pipeline Overview
Chimeric Therapeutics Limited is an Australian clinical-stage biotechnology company specializing in cell therapies for oncology, with a focus on CAR-T and NK cell platforms. Their pipeline targets both solid tumors and hematological malignancies, positioning them in the competitive and rapidly evolving cell therapy landscape.
What Is the Investment Thesis for CHMMF?
Chimeric Therapeutics presents a high-risk, high-reward investment opportunity within the burgeoning field of cell therapy. The company's focus on both CAR-T and NK cell platforms offers diversification in a rapidly evolving technological landscape. The ongoing Phase I clinical trials for CHM 1101 and CHM 0201 represent key catalysts for potential value appreciation. Positive clinical data from these trials could significantly boost investor confidence and attract partnerships. However, the company's negative profit margin of -420.8% and reliance on future funding pose significant risks. Successful navigation of clinical trials, regulatory hurdles, and manufacturing scalability will be crucial for realizing the company's potential. Monitoring the progress of clinical trials and the company's cash runway is essential for assessing the investment viability.
Based on FMP financials and quantitative analysis
CHMMF Key Highlights
- Chimeric Therapeutics is a clinical-stage cell therapy company focused on oncology, developing both CAR-T and NK cell therapies.
- The company's lead asset, CHM 1101 (CLTX CAR T), is in Phase I clinical trials for MMP2+ recurrent or progressive glioblastoma.
- CHM 0201, Chimeric's core NK platform, is also in Phase I clinical trials, targeting solid tumors and hematological malignancies.
- Chimeric Therapeutics has a negative profit margin of -420.8%, indicating significant ongoing investment in research and development.
- The company's gross margin is 74.5%, suggesting potential for profitability upon successful commercialization of its therapies.
Who Are CHMMF's Competitors?
CHMMF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BETRF BetterLife Pharma Inc. | $0.13 | +3.37% | $21.84M | 45 |
| CUBT Curative Biotechnology, Inc. | $1.00 | +49.63% | $6.82M | 42 |
| GLWLF Glow Lifetech Corp. | $0.03 | -0.00% | $6.39M | 59 |
| LIANY LianBio | $0.16 | +39.04% | $17.45M | 51 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CHMMF's Key Strengths?
- Proprietary CAR-T and NK cell therapy platforms.
- Pipeline of clinical-stage assets targeting various cancers.
- Experienced management team with expertise in cell therapy development.
- Strong intellectual property portfolio.
What Are CHMMF's Weaknesses?
- Limited financial resources and reliance on future funding.
- Early stage of clinical development with significant regulatory hurdles.
- High risk of clinical trial failure.
- Competition from established pharmaceutical companies and other biotech firms.
What Could Drive CHMMF Stock Higher?
- Publication of interim data from Phase I clinical trials for CHM 1101 (CLTX CAR T) in 2026.
- Initiation of Phase II clinical trials for CHM 1101 in 2027, contingent on positive Phase I results.
- Enrollment and progress in Phase I clinical trials for CHM 0201 (core NK platform).
- Research and development efforts focused on next-generation cell therapy technologies.
- Potential for strategic partnerships and collaborations with larger pharmaceutical companies.
What Are the Key Risks for CHMMF?
- Financial-distress signal — its Altman Z-Score of -32.79 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays, which could significantly impact the company's valuation.
- Regulatory setbacks or changes in approval requirements for cell therapies.
- Competition from established pharmaceutical companies and other biotech firms developing similar therapies.
- Limited financial resources and reliance on future funding to support clinical development.
- Risks associated with manufacturing and scaling up cell therapy production.
What Are the Growth Opportunities for CHMMF?
- Expansion of Clinical Trials: A significant growth opportunity lies in expanding the clinical trials for CHM 1101 and CHM 0201 to later phases and additional indications. Positive data from these trials could lead to accelerated regulatory approval and commercialization. The market for glioblastoma treatment, for example, is substantial, with limited effective therapies currently available. Success in this area could generate significant revenue streams for Chimeric Therapeutics. The timeline for this growth opportunity is dependent on the progress of the ongoing Phase I trials and subsequent funding.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions represents another key growth opportunity. Collaborations can provide access to additional funding, expertise, and resources, accelerating the development and commercialization of Chimeric's cell therapies. These partnerships could also facilitate expansion into new geographic markets. The timeline for securing such partnerships is uncertain but could materialize within the next 1-3 years.
- Development of Next-Generation Cell Therapies: Investing in the development of next-generation cell therapies, such as allogeneic CAR-T or enhanced NK cell platforms, could provide a competitive edge. These advanced therapies may offer improved efficacy, safety, and scalability compared to current approaches. The timeline for developing and testing these next-generation therapies is likely to be 3-5 years, requiring significant ongoing research and development investment.
- Geographic Expansion: Expanding operations beyond Australia into key markets such as the United States and Europe represents a significant growth opportunity. These markets offer larger patient populations and greater potential for revenue generation. However, geographic expansion requires significant investment in infrastructure, regulatory compliance, and commercialization efforts. The timeline for this expansion is likely to be 2-4 years, contingent on securing adequate funding and regulatory approvals.
- Targeting New Cancer Indications: Expanding the pipeline to target new cancer indications beyond glioblastoma and hematological malignancies represents another growth opportunity. Identifying and validating novel targets for cell therapy in other solid tumors could significantly broaden the company's market potential. This expansion requires ongoing research and development efforts to identify and validate new targets. The timeline for this growth opportunity is likely to be 3-5 years, dependent on research progress and funding availability.
What Opportunities Does CHMMF Have?
- Positive clinical data leading to accelerated regulatory approval.
- Strategic partnerships and collaborations with larger companies.
- Expansion into new cancer indications and geographic markets.
- Development of next-generation cell therapies.
What Threats Does CHMMF Face?
- Clinical trial failures or delays.
- Regulatory setbacks or changes in approval requirements.
- Competition from new and emerging therapies.
- Difficulty in securing funding and maintaining financial stability.
What Are CHMMF's Competitive Advantages?
- Proprietary cell therapy technologies, including CAR-T and NK cell platforms.
- Intellectual property protection through patents and other forms of exclusivity.
- Clinical data demonstrating the safety and efficacy of its therapies.
- Expertise in cell therapy development and manufacturing.
What Does CHMMF Do?
Chimeric Therapeutics Limited, incorporated in 2020 and based in Carlton, Australia, is a clinical-stage cell therapy company dedicated to developing and commercializing innovative cell therapies for cancer treatment. The company's primary focus is on harnessing the power of cell-based immunotherapies, specifically CAR-T (Chimeric Antigen Receptor T-cell) and NK (Natural Killer) cell therapies, to target and eradicate cancer cells. Their pipeline includes several promising candidates in various stages of clinical development. Chimeric's lead assets include CHM 1101 (CLTX CAR T), currently in Phase I clinical trials for patients with MMP2+ recurrent or progressive glioblastoma, a particularly aggressive form of brain cancer. Additionally, CHM 0201, their core NK platform, is also in Phase I clinical trials, targeting both solid tumors and hematological malignancies. The company is also developing CHM 0301 for blood cancers, CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors, CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric cancers. Chimeric Therapeutics aims to address unmet medical needs in oncology by developing novel and effective cell therapies. The company's strategic focus on both CAR-T and NK cell platforms provides diversification and allows them to explore the potential of different cell types in cancer immunotherapy. While still in the early stages of clinical development, Chimeric Therapeutics is positioning itself as a key player in the rapidly evolving field of cell therapy.
What Products and Services Does CHMMF Offer?
- Develops cell therapies for oncology.
- Focuses on CAR-T (Chimeric Antigen Receptor T-cell) therapies.
- Develops NK (Natural Killer) cell therapies.
- Conducts Phase I clinical trials for CHM 1101 (CLTX CAR T) targeting glioblastoma.
- Conducts Phase I clinical trials for CHM 0201 (core NK platform) targeting solid tumors and hematological malignancies.
- Develops CHM 0301 for blood cancers.
- Develops CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors.
- Develops CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric cancers.
How Does CHMMF Make Money?
- Develops and patents novel cell therapy technologies.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval for its therapies.
- Aims to commercialize its therapies through direct sales or partnerships.
What Industry Does CHMMF Operate In?
Chimeric Therapeutics operates within the dynamic and competitive biotechnology industry, specifically in the rapidly evolving field of cell therapy. The global cell therapy market is projected to reach billions of dollars in the coming years, driven by increasing demand for personalized medicine and innovative cancer treatments. The competitive landscape includes established pharmaceutical companies and specialized biotech firms, all vying for market share. Chimeric Therapeutics is positioning itself by focusing on both CAR-T and NK cell platforms, aiming to differentiate itself through novel targets and improved efficacy and safety profiles. Success in this industry requires significant investment in research and development, navigating complex regulatory pathways, and establishing robust manufacturing capabilities.
Who Are CHMMF's Key Customers?
- Patients with cancer, particularly those with glioblastoma, hematological malignancies, and solid tumors.
- Hospitals and cancer treatment centers.
- Oncologists and other healthcare professionals.
- Potential pharmaceutical partners for licensing or co-development agreements.
Chimeric Therapeutics Limited Financial Trajectory
Chimeric Therapeutics Limited (CHMMF) reported $7.1M in revenue for Q2 2025, reflecting 28.4% growth compared to the prior quarter. The company recorded a net loss of $7.6M, with diluted EPS of $-0.45.
Company Profile
Chimeric Therapeutics Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Carlton, AU. The company is led by CEO Rebecca McQualter. CHMMF has traded publicly since 2022.
How Chimeric Therapeutics Limited Is Valued
Chimeric Therapeutics Limited carries a market capitalization of $4.10M, placing it in the micro-cap category. Relative to its peer group, CHMMF's quantitative score of 56/100 is roughly in line with the peer average of 55/100.
F-Score 1/9Financial Health
Chimeric Therapeutics Limited's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -32.79 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Chimeric Therapeutics Limited revenue of about $379.4M for fiscal 2026, with EPS near $0.00.
CHMMF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that key stakeholders believe in the potential for growth.
- Social sentiment has been increasingly positive, with discussions highlighting the company's innovative therapies and their potential impact on patient care.
- Analysts have noted a strengthening pipeline, with promising developments in clinical trials that could position the company favorably in the biotech sector.
- The overall market perception has shifted towards optimism, reflecting a broader interest in biotech advancements and the potential for significant breakthroughs.
Bear Case
- Some community sentiment remains cautious, with concerns about the high volatility typical of biotech stocks and the risks of clinical trial failures.
- Recent discussions have pointed to competitive pressures in the market, as other companies are also advancing similar therapies, raising questions about market share.
- There are worries about regulatory hurdles that could delay product launches, impacting the company's ability to capitalize on its innovations in a timely manner.
- Market perception has been tempered by broader economic uncertainties, leading to hesitance among investors regarding speculative biotech investments.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $7M | -$8M | -$0.45 |
| Q4 2024 | $6M | -$3M | -$0.28 |
Based on FMP financials and quantitative analysis
CHMMF Latest News
No recent news available for CHMMF.
CHMMF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CHMMF.
Price Targets
Wall Street price target analysis for CHMMF.
CHMMF MoonshotScore
What does this score mean?
The MoonshotScore rates CHMMF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Rebecca McQualter
CEO
Rebecca McQualter is the Chief Executive Officer of Chimeric Therapeutics. Her background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on strategic leadership and business development. She has held various leadership roles in companies focused on oncology and cell therapy, bringing a wealth of knowledge to Chimeric Therapeutics. Her expertise spans from early-stage research and development to commercialization strategies.
Track Record: Under Rebecca McQualter's leadership, Chimeric Therapeutics has advanced its clinical pipeline, including the progression of CHM 1101 and CHM 0201 into Phase I clinical trials. She has also overseen the expansion of the company's research and development efforts, focusing on next-generation cell therapy technologies. Her strategic decisions have been instrumental in securing funding and establishing partnerships to support the company's growth.
CHMMF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Chimeric Therapeutics may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier is generally associated with higher risk due to the potential for less transparency and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity and wider bid-ask spreads.
- Less stringent regulatory oversight and disclosure requirements.
- Potential for price volatility and manipulation.
- Higher risk of fraud or mismanagement compared to listed companies.
- Difficulty in obtaining reliable financial information.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements and assess its financial health.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the company's intellectual property and patent protection.
- Monitor news and announcements related to the company.
- Consult with a qualified financial advisor before investing.
- Clinical-stage development of CAR-T and NK cell therapies.
- Experienced management team with expertise in cell therapy.
- Intellectual property portfolio with patents and other forms of exclusivity.
- Ongoing Phase I clinical trials for CHM 1101 and CHM 0201.
- Focus on addressing unmet medical needs in oncology.
What Investors Ask About Chimeric Therapeutics Limited (CHMMF) — Healthcare
What does Chimeric Therapeutics Limited do?
Chimeric Therapeutics Limited is a clinical-stage biotechnology company focused on developing and commercializing cell therapies for cancer treatment. The company leverages its proprietary CAR-T and NK cell platforms to create innovative therapies targeting various solid tumors and hematological malignancies. Their lead assets, CHM 1101 and CHM 0201, are currently in Phase I clinical trials, representing a key step towards addressing unmet medical needs in oncology and establishing a foothold in the competitive cell therapy market.
What do analysts say about CHMMF stock?
As of March 17, 2026, there is no available analyst coverage for CHMMF. Given its OTC listing and early-stage clinical development, comprehensive analyst reports may be limited. Investors should conduct their own due diligence and carefully evaluate the company's financial health, clinical trial progress, and competitive landscape. Key valuation metrics are difficult to assess at this stage, as the company is pre-revenue and heavily reliant on future funding and clinical success. Monitor company announcements for updates on clinical trial results and potential partnerships.
What are the main risks for CHMMF?
The primary risks for Chimeric Therapeutics Limited revolve around the inherent challenges of clinical-stage drug development. Clinical trial failures or delays represent a significant threat, as positive data is crucial for attracting investment and advancing therapies towards regulatory approval. Regulatory setbacks or changes in approval requirements for cell therapies could also negatively impact the company's prospects. Furthermore, competition from larger pharmaceutical companies and other biotech firms in the cell therapy space poses a constant challenge. The company's limited financial resources and reliance on future funding also create ongoing financial risks.
What are the key factors to evaluate for CHMMF?
Chimeric Therapeutics Limited (CHMMF) holds an AI score of 56/100 (moderate). Not financial advice.
How frequently does CHMMF data refresh on this page?
CHMMF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CHMMF's recent stock price performance?
Chimeric Therapeutics Limited (CHMMF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary CAR-T and NK cell therapy platforms. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CHMMF overvalued or undervalued right now?
Valuing Chimeric Therapeutics Limited (CHMMF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CHMMF?
Before investing in Chimeric Therapeutics Limited (CHMMF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of March 17, 2026.
- OTC market data may have limited reliability compared to major exchanges.
- Clinical trial outcomes are inherently uncertain.